| Market Capitalization (Millions $) |
24 |
| Shares
Outstanding (Millions) |
11 |
| Employees |
16 |
| Revenues (TTM) (Millions $) |
56 |
| Net Income (TTM) (Millions $) |
-34 |
| Cash Flow (TTM) (Millions $) |
9 |
| Capital Exp. (TTM) (Millions $) |
3 |
Business Description
Aytu BioPharma Inc. is a specialty pharmaceutical company that focuses on developing and commercializing innovative products in the areas of urology, women's health, and sleep disorders. The company is headquartered in Englewood, Colorado and was founded in 201
The company's urology product portfolio includes Natesto, a nasal testosterone replacement therapy (TRT) for adult males diagnosed with hypogonadism; ProstaScint, a radioactive imaging agent for prostate cancer detection; and MiOXSYS, a male infertility diagnostic platform that measures oxidative stress levels in semen samples.
In the women's health sector, Aytu BioPharma produces Tuzistra XR, an extended-release cough syrup designed to treat acute coughing symptoms. The company also recently acquired a product called ZolpiMist, a prescription sleep aid that delivers a fine mist of zolpidem tartrate, which is a sedative-hypnotic drug.
Aytu BioPharma has a diverse and robust pipeline of products in various stages of development that target diseases in urology, endocrinology, and infectious diseases. The company has several strategic collaborations, including a licensing agreement with Acerus Pharmaceuticals for the distribution of Natesto in Canada and a partnership with Innovus Pharmaceuticals for the development and commercialization of products in women's health.
Aytu BioPharma is committed to improving patient outcomes by providing innovative and effective treatments for unmet medical needs. The company has a strong financial position, with a cash balance of $24 million as of June 30, 2020, and has recently reported positive revenue growth. Additionally, Aytu BioPharma has been actively involved in efforts to combat COVID-19, with the distribution of a rapid COVID-19 test and the acquisition of certain assets from Cerecor Inc. for the development of a COVID-19 treatment.
Company Address: 7900 East Union Avenue, Suite 920 Denver 80237 CO
Company Phone Number: 437-6580 Stock Exchange / Ticker: NASDAQ AYTU
|
14.29% 
107 %